May 2, 2022

Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

– The CRL requests a quality process change Junshi Biosciences and Coherus believe is readily addressable – – BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline – – Onsite inspections in China, impeded to date by COVID-19-related travel restrictions, are required for FDA’s completion of BLA review – – Toripalimab will be the first and […]

Read More

EU Says Apple Pay May Violate EU Antitrust Laws

The European Union on Monday accused Apple of abusing its dominant Apple Pay market position to prevent other companies from competing in contactless payment technologies.”Apple has built a closed ecosystem around its devices and its operating system, …

Read More

Recent Posts